Reference is being made to the stock exchange release from 3 October 2022 where Arctic Bioscience gave a status update related to the submission of the Clinical Trial Application (CTA) for a Phase IIb clinical trial in mild-to-moderate psoriasis with the investigational medicinal product (IMP) HRO350.
Arctic Bioscience is pleased to announce that the CTA has been submitted. Approval of CTA by authorities will allow for the first patient to be enrolled in the Phase IIb clinical trial as planned in Q4 2022. Sites for the clinical trial with access to sufficient number of patients to conduct the studies are localized in five European countries.
“We are pleased that the CTA has been submitted. This is an important step in our drug development journey and vital for the HRO350 Phase IIb clinical trial”, says Christer L. Valderhaug, CEO of Arctic Bioscience.
The CTA contains key information about the IMP HRO350 and the planned clinical trial activities.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Christer L. Valderhaug
CEO of Arctic Bioscience AS
Mobile: +47 920 84 601
Jone R. Slinning
CFO of Arctic Bioscience AS
Mobile: +47 948 75 469
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.